Arsenic induces apoptosis of multidrug-resistant human myeloid leukemia cells thin express Bcr-Abl or overexpress MDR, MRP, Bcl-2, or Bcl-x(L)

Blood

Volumn 95, Issue 3, 2000, Pages 1014-1022

  Perkins, Charles ^b   Kim, Caryn N ^b   Fang, Guofu ^b   Bhalla, Kapil N ^a  

^a UNIVERSITY OF MIAMI   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC; HISTONE; PROTEIN BCL 2; PROTEIN BCL X; REACTIVE OXYGEN METABOLITE;

ACETYLATION; APOPTOSIS; ARTICLE; CELL DIFFERENTIATION; CELL MEMBRANE POTENTIAL; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; LEUKEMIA CELL; MULTIDRUG RESISTANCE; MYELOID LEUKEMIA; PRIORITY JOURNAL;

EID: 0034142368     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v95.3.1014.003k04_1014_1022     Document Type: Article

References (54)

1. Soignet S, Maslak P, Wang ZG, et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med. 1998;339:1341.
2. Look AT. Arsenic and apoptosis in the treatment of acute promyelocytic leukemia. J Natl Cancer Inst. 1998;90:86.
3. 3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RARα/PML proteins. Blood. 1996;88:1052.
4. 3 exerts dose-dependent dual effects on APL cells. Blood. 1997; 89:3345.
5. Wang ZG, Rivi R, Delva L, et al. Arsenic trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in a PML and PML-RARα independent manner. Blood. 1998;92:1497.
6. Rousselo P, Labaume S, Maralleau J, et al. Arsenic trioxide and melarsoprol induce apoptosis in plasma cell lines and in plasma cells from myeloma patients. Cancer Res. 1999;59:1041.
7. Bazarbachi A, El-Sabban M, Nasr R, et al. Arsenic trioxide and interferon-α synergize to induce cell cycle arrest and apoptosis in human T-cell lymphotropic virus type I-transformed cells. Blood. 1999;93:278.
8. Konig A, Wrazel L, Warrell R Jr, et al. Comparative activity of melarsoprol and arsenic trioxide in chronic B-cell leukemia lines. Blood. 1997;90: 562.
9. Yang J, Liu X, Bhalla K, et al. Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science. 1997;275:1129.
10. Adams J, Cory S. The Bcl-2 protein family: arbiters of cell survival. Science. 1998;281:1322.
11. Perkins C, Kim C, Fang G, Bhalla K. Overexpression of Apaf-1 promotes apoptosis of untreated and paxlitaxel- or etoposide-treated HL-60 cells. Cancer Res. 1998;58:4561.
12. Green D, Reed J. Mitochondria and apoptosis. Science. 1998;281:1309.
13. Hockenbery D, Oltvai Z, Yin XM, Milliman C, Korsmeyer. Bcl-2 functions in an antioxidant pathway to prevent apoptosis. Cell. 1993;75:241.
14. Dai J, Weinberg RS, Waxman S, Jing Y. Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system. Blood. 1999;93:268.
15. Huang Y, Ibrado AM, Reed JC, et al. Co-expression of several molecular mechanisms of multidrug resistance and their significance for paclitaxel cytotoxicity in human AML HL-60 cells. Leukemia. 1997;11:253.
16. Bedi A, Barber JP, Bedi GC, et al. BCR-ABL-mediated inhibition of apoptosis with delay of G2/M transition after DNA damage: a mechanism of resistance to multiple anticancer agents. Blood. 1995;86:1148.
17. McGahon A, Bissonnette R, Schmitt M, Cotter KM, Green DR, Cotter TG. BCR-ABL maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death. Blood 1994;83:1179.
18. Amarante-Mendes G, Kim C, Liu L, et al. Bcr-Abl exerts its antiapoptotic effect against diverse apoptotic stimuli through blockage of mitochondrial release of cytochrome c and activation of caspase-3. Blood. 1998;91:1700.
19. κB). Oncogene. 1997;15:2267.
20. κB. Science. 1996;274:784.
21. Warrell R Jr, He LZ, Richon V, Calleja E, Pandolfi PP. Accelerated discovery: therapeutic targeting of transcription of acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. J Natl Cancer Inst. 1998;90:1621.
22. Richon V, Emiliani S, Verdin E, et al. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc Natl Acad Sci U S A. 1998;95:3003.
23. Kuo MH, Allis D. Roles of histones acetyltransferases and deacetylases in gene regulation. Bioessays. 1998;20:615.
24. Liu X, Zou H, Slaughter C, Wang X, DFF, a heterodimeric protein that functions downstream of caspase-3 to trigger DNA fragmentation during apoptosis. Cell. 1997;89:175.
25. Zou H, Henzel WJ, Liu X, Lutschg A, Wang X. Apaf-1, a human protein homologous to C. elegans CED-4, participated in cytochrome c-dependent activation of caspase-3. Cell. 1997;90: 405.
26. Luo X, Budihardjo I, Zou H, Slaughter C, Wang X. Bid, a Bcl-2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell. 1998;94:481.
27. L inhibits Ara-C-induced CPP32/Yama protease activity and apoptosis of human acute myelogenous leukemia HL-60 cells. Cancer Res. 1996;56:4743.
28. Lozzio CB, Lozzio BB. Human chronic myelogenous leukemia cell line with positive Philadelphia chromosome. Blood. 1975;45:321.
29. Bhalla K, Hindenburg A, Taub R, Grant S. Isolation and characterization of an anthracycline-resistant human leukemic cell line. Cancer Res. 1985;45:3657.
30. L Overexpression inhibits taxol- induced Yama protease activity and apoptosis. Cell Growth & Differ 7: 1087, 1996
31. L antagonize the mitochondrial dysfunction preceding nuclear apoptosis induced by chemotherapeutic agents. Cancer Res 1997;57:62.
32. Xiang J, Chao DT, Korsmeyer SJ. BAX-induced cell death may not require interteukin 1 β-converting enzyme-like proteases. Proc Natl Acad Sci U S A. 1996;93:14,559.
33. Freemerman AJ, Vrana JA, Tombes RM, et al. Effects of antisense p21 (WAF1/CIP1/MDA6) expression on the induction of differentiation and drug-mediated apoptosis in human myeloid leukemia cells (HI-60). Leukemia. 1997;11:504.
34. Li YM, Broome J. Arsenic targets tubulins to induce apoptosis in myeloid leukemia cells. Cancer Res. 1999;59:776.
35. S induces differentiation and sensitizes chronic myelogenous leukemia-blast crisis K562 cells to 1-B-D-Arabinofuranosylcytosine-mediated differentiation and apoptosis. Cell Growth Differ. 1996;7:1617.
36. Ray S, Ponnathpur V, Huang Y, et al. 1-β-D-arabinofuranosylcytosine-, mitoxantrone- and paclitaxel-induced apoptosis in HL-60 cells: improved method for detection of internucleosomal DNA fragmentation. Cancer Chemother Pharmacol. 1994;34:365.
37. Koopman G, Reutelingsperger CPM, Kuijten GAM, Keehnen RMJ, Pals ST, van Oers MHJ. Annexin-V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood. 1994;84:1415.
38. Enari M, Sakahira H, Yokoyama H, Okawa K, Iwamatsu A, Nagata S. A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD. Nature. 1998;391:43.
39. Tang D, Kidd V. Cleavage of DFF-45/ICAD by multiple caspases is essential for its function during apoptosis. J Biol Chem.1998;273:28,549.
40. Li P, Nijhawan D, Budihardjo I, et al. Cytochrome c and dATP-dependent formation of Apaf-1/ caspase-9 complex initiates an apoptotic protease cascade. Cell. 1997;91:479.
41. Wang K, Yin XM, Chao DT, Milliman CL, Korsmeyer SJ. BID: a novel BH3 domain-only death agonist. Genes Dev. 1996;10:2859.
42. Luo R, Postigo A, Dean D. Rb Interacts with histone deacetylase to repress transcription. Cell. 1998;92:463.
43. Zhu X-H, Shen Y-L, Jing Y-k, et al. Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations. J Natl Cancer Inst. 1999;91: 772.
44. Kroemer G, de Thé H. Arsenic trioxide, a novel mitochondriotoxic anticancer agent? J Natl Cancer Inst. 1999; 91:743.
45. Green D. Apoptotic pathways: the roads to ruin. Cell. 1998;94:695.
46. Ibrado AM, Kim CN, Bhalla K. Temporal relationship of CDK1 activation and mitotic arrest to cytosolic accumulation of cytochrome C and caspase-3 activity during Taxol-induced apoptosis of human AML HL-60 cells. Leukemia. 1998; 12:1930.
47. L. Oncogene. 1998;16:1383.
48. Szczylik C, Skorski T, Nicolaides N, et al. Selective inhibition of leukemia cell proliferation by Bcr-Abl antisense oligodeoxynucleotides. Science. 1991;253:562.
49. le Courte P, Malogni L, Cleris L, et al. In vitro eradication of human Bcr/Abl-positive leukemia cells with an ABL kinase inhibitor. J Natl Cancer Inst. 1999;91:163.
50. L through caspase interaction. Proc Natl Acad Sci U S A. 1998;95:554.
51. L protein by caspase-3-like proteases. Oncogene. 1998;7:1295.
52. Imof A, Wolffe A. Transcription: gene control by targeted histone acetylation. Curr Biol. 1998;8: 422.
53. Ait-Si-Ali S, Ramirez S, Barre F-X, et al. Histone acetyltransterase activity of CBP is controlled by cycle-dependent kinases and oncoprotein E1A. Nature. 1998;396:184.
54. Boyes J, Byfield P, Nakatani Y, Ogryzko V. Regulation of activity of the transcription factor GATA-1 by acetylation. Nature. 1998;396:594.